A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Study duration: * Screening period: up to 56 days * Transition period between last sutimlimab dose and first dose of BIVV020 (for participants who were previously receiving sutimlimab): 14 days, included as part of the 56-day Screening period. Treatment duration: Minimum 52 weeks. Visit frequency: * Day 1 * Day 4 * Weeks 1 to 6: Weekly * Weeks 7 to 12: Every other week * Weeks 13 to 24: Every 4 weeks * Weeks 25+: At least every 8 weeks * End of Study visit: 22 weeks after the last dose of BIVV020